Fucus evanescens |
Etoposide |
Human malignant lymphoid cell lines, MT-4 and Namalwa |
Enhanced etoposide-induced caspase dependent cell death pathway in MT-4 but not Namalwa cell line |
Presensitisation with 500 micrograms/mL fucoidan, prior to etopside treatment |
Philchenkov et al. [64] |
Cladosiphon sp. prepared by enzymatic digestion |
Cisplatin, tamoxifen or paclitaxel |
MDA-MB-231 and MCF7 breast cancer cells. |
Down-regulation Bcl-xL Mcl-1. Decreased phosphorylation of ERK and Akt in MDA cells, increased phosphorylation of ERK in MCF-7 cells. Increased intracellular ROS, reduced glutathione (GSH) |
Fucoidan extract at 200 and 400 micrograms/mL concurrently with chemotherapy drugs |
Zhang et al. [63] |
Unknown source or composition fucoidan preparation |
Lapatinib |
EGFR/ERBB2-amplified cancer cell lines |
Synergistically inhibit OE33 but antagonized in ESO26, NCI-N87, and OE19 |
10 to 1000 micrograms/mL |
Oh et al. [62] |